

## Special Issue

# Promoting Research, Development and Access to Vaccines to Address Global Inequities

### Message from the Guest Editor

Vaccines are a highly effective public health measure for promoting population health. However, the COVID-19 pandemic, monkeypox, and other global public health emergencies have highlighted serious global inequality in the development and accessibility of vaccines, particularly in disadvantaged settings. It is essential to address these issues by understanding the current situation, analyzing its reasons, and exploring potential solutions. We invite original research articles and reviews on a wide range of topics related to global vaccine equity issues, including routine and emergency vaccines for all age groups. This includes, but is not limited to, vaccine hesitancy, vaccination promotion interventions, relevant economic evaluations, and vaccination for vulnerable populations. We are eagerly looking forward to receiving your contributions.

### Guest Editor

Dr. Yangmu Huang

Department of Global Health, School of Public Health, Peking University, Beijing 100191, China

### Deadline for manuscript submissions

31 October 2025



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/194880](https://mdpi.com/si/194880)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).